<?xml version="1.0" encoding="UTF-8"?>
<p>Switching focus in his Elion lecture, Mike summarised his recent work at Arbutus. Their strategy for an HBV cure is to minimise the levels of HBV antigens and thereby to restore the host immune response. There has been good progress setting up in vitro and 
 <italic>in vivo</italic> screens in which novel approaches are being evaluated. Mike is evaluating David Chuâ€™s novel nucleoside analogue, FMCA.
</p>
